Identification of Alpha-synuclein Pathology in Idiopathic Rapid Eye Movement Sleep Disorder Participants by Seed Amplification Assay
Objective: To assess correlations between cerebrospinal fluid (CSF) α-synuclein seed amplification assay (synSAA) and the phenoconversion rate, timing, and final diagnosis of idiopathic rapid eye…Defining a Population-Based Cohort of Individuals with Probable REM Sleep Behavior Disorder
Objective: To identify a large population-based probable REM sleep behavior disorder (pRBD) cohort of women who are at risk of phenoconversion to Parkinson’s disease (PD)…A highly specific skin α-synuclein seed amplification assay for screening of synucleionpathies
Objective: To evaluate the performance of a skin α-synuclein seed amplification assay (skin_synSAA) as a screening test using samples from movement disorder subjects with uncertain…Cerebellar α-Synucleinopathy Contributes to Gait and Balance Impairment in Parkinson’s Disease
Objective: To determine whether cerebellar α-synuclein (α-syn) pathology contributes to the onset and progression of postural instability and gait difficulty (PIGD)-like motor deficits in Parkinson’s…Large-Scale Shotgun Mass Spectrometry in Parkinson’s Disease Plasma Identifies Novel Biomarker Candidates
Objective: To identify novel Parkinson’s disease (PD) blood biomarkers using unbiased shotgun mass spectrometry. Background: PD is a common neurodegenerative disorder diagnosed based on its…Dietary and Environmental Risk Factors of Parkinson’s Disease: An Integrated Network Pharmacology Approach
Objective: To investigate dietary and environmental determinants of Parkinson’s disease (PD) and related mortality by integrating large-scale clinical phenotyping with network pharmacology and molecular docking…smSAA: developing a quantitative seed amplification assay with single molecule spectroscopy
Objective: Alpha-synuclein seed amplification assays (SAA) are highly sensitive and specific for detecting endogenous alpha-synuclein (Syn) seeds and are emerging as diagnostic tools for early…Disassembly of α-Synuclein Aggregates by the All-D-peptide PRI-101: Preclinical Efficacy in Vitro and in Vivo.
Objective: To develop a disease-modifying therapy for Parkinson’s disease (PD) and related synucleinopathies by eliminating intracellular, toxic, and seeding-competent aggregate species of α-synuclein (α-syn). Background:…Regional α-Synuclein Seeding Activity in Parkinson’s disease and Multiple System Atrophy
Objective: This study aimed to profile regional α‑synuclein (α-syn) seeding activity in postmortem brains from Parkinson’s disease (PD) and multiple system atrophy (MSA) and to…Underestimation of Nighttime Sleep Symptoms in Isolated RBD is Associated with Increased Risk of Phenoconversion to Synucleinopathy: A North American Prodromal Synucleinopathy Consortium Study
Objective: To determine whether mismatch between participant (PT) self-perceived and bed partner (BP)–reported sleep symptoms is associated with risk of phenoconversion to synucleinopathy. Background: Patients…
- 1
- 2
- 3
- …
- 18
- Next Page »